Pharmaceutical

EASD 2024: Are tetra-agonists the future of metabolic diseases treatment?

EASD 2024 participants are looking for the hottest efficacy data to make predictions on the next trend in the metabolic space.

Sep 12, 2024 - 04:00
EASD 2024: Are tetra-agonists the future of metabolic diseases treatment?
EASD 2024 participants are looking for the hottest efficacy data to make predictions on the next trend in the metabolic space.
Read the original article

Tags:

Previous Article

FDA approves Johnson & Johnson’s TREMFYA for ulcerative colitis

Next Article

IBA venture PanTera gains €134m in funding to scale up actinium-225 production

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Santhera’s DMD therapy Agamree approved for NHS use after new price deal

Santhera’s DMD therapy Agamree approved for NHS use aft...

Dec 11, 2024

EMA committee rethinks stance and recommends Leqembi for Alzheimer’s disease

EMA committee rethinks stance and recommends Leqembi fo...

Nov 15, 2024

Atypical Teratoid Rhabdoid Tumor drugs in development, ...

Aug 31, 2024